Transmembrane proteins (TPs) serve as crucial conduits between the internal and external environments of cells, regulating ion and molecule passage and orchestrating cellular responses to external cues. They play pivotal roles in cellular signaling, cell-cell interactions, and various physiological processes, making them promising targets for novel therapeutics, including cell and gene therapies. Leveraging the unique properties of TPs, researchers can design targeted therapeutic strategies with improved efficacy, specificity, and safety profiles.

 

However, isolating biologically relevant forms of TPs, particularly multi-pass TPs, presents formidable challenges due to their intricate structures and limited expression levels. Addressing this demand, ACROBiosystems has pioneered cutting-edge technology platforms tailored to the complexities of multi-pass TPs. This innovation has yielded a comprehensive suite of full-length, stabilized multi-pass TPs, including key therapeutic targets such as CD20, Claudin18.2, CD133, and others. Engineered to maintain native folding and high activity, these proteins serve as invaluable tools for advancing drug development and uncovering novel mechanisms of action.

 

In collaboration with Nicoya, a cutting-edge technology company dedicated to supporting drug development through advanced analytical solutions, Nicoya’s Alto™ digital surface plasmon resonance (SPR) system was utilized to characterize the binding kinetics of several transmembrane proteins in detergent, nanodisc, and virus-like particle (VLP) formats. This webinar will showcase how the Alto digital SPR system provides high-quality data on challenging membrane protein candidates while significantly reducing sample consumption and time to results. Through this collaboration, researchers and pharmaceutical developers gain access to advanced technologies that enable the production, stabilization and precise characterization of challenging transmembrane protein interactions, accelerating the development of novel therapeutics and unlocking new frontiers in therapeutic targeting.

 

Learning Objectives